Business, energy, technology, markets and global industry news from Business News Today

TIVDAK

PharmaDeviceNews TIVDAK
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Representative image of cervical cancer treatment planning as Zai Lab’s TIVDAK approval expands China’s options for recurrent or metastatic disease.
Pharma & Biotech

TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains

TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.

Read More